After the whopping $7.2 billion sale of his last venture, Receptos, to Celgene back in 2015, Marcus Boehm wasn’t supposed to start another company. He was going to take a backseat, for once. Consult. Be on a few boards.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,